Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by IrishCanuckon Jan 04, 2021 3:54am
306 Views
Post# 32213394

RE:2021 January

RE:2021 January Good luck to everyone except Duster! 

I think the upcoming 12 months will be exciting... unless there is dilution. I think we can hit several catalysts by July and then there are another six months of buffer room I hope we don't need. Hopefully Citagenix is sold off to reduce the pressure of raising cash.

I think 600M has been thrown around a few times (are we saying that's CAD too, not USD?). That gets us to $15.50 per share which is tantilizing and essentially the price target floating out there. Less than half a billion USD market cap should absolutely attract attention. But add on ATB-352 for Phase 1 and its ability to fast track FDA application for the opioid crisis... combined 1 billion CAD should be easy for two independent drugs and that's $25.85.

I think a lot of things have been pushed back over the last two years with delays so I hope they're finally fitting in a lot for 2021!!! Good luck! 
<< Previous
Bullboard Posts
Next >>